Pharmaceutical News

RSS

Nanotherapeutics receives contract from DOD to support clinical trial for treating dehisced surgical wounds

Nanotherapeutics, Inc. announced that it has been awarded a contract by the U.S. Department of Defense to support a clinical trial for treating dehisced surgical wounds with the Company's NanoDOX Hydrogel, a topical doxycycline hydrogel for chronic wounds.

4 Nov 2010

FIP Annual Meeting to improve global health through advances in pharmaceutical sciences

Global health crises like the recent cholera outbreak in Haiti emphasize the need for new ways to prevent deadly diseases from becoming widespread in developing countries. International experts and scientists will present research ranging from developing a freeze-dried cholera vaccine to new methods of delivering medicines to underserved populations at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in New Orleans, La., Nov. 13-18.

4 Nov 2010

Cardium receives $245,000 grant under QTDP program

Cardium Therapeutics today announced that it was awarded a cash grant of approximately $245,000 under the U.S. Government's Qualifying Therapeutic Discovery Project program to further its Generx clinical development program.

4 Nov 2010

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Spectrum Pharmaceuticals, Inc. a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it has been awarded grants totaling $977,900 under the Qualifying Therapeutic Discovery Project (QTDP) Program administered under section 48D of the Internal Revenue Code.

4 Nov 2010

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Acton Pharmaceuticals, Inc. today announced that it has submitted to the U.S. Food and Drug Administration (FDA), a Manufacturing Supplement to the previously approved AEROSPAN Inhalation Aerosol NDA.

4 Nov 2010

Pharma in Asia-Pacific region becomes more active in R&D, study finds

In recent years, pharmaceutical companies in the Asia-Pacific region have ramped up their clinical trial activity, patent challenges of brand name drugs and their development of new products, according to report released Tuesday by CMR International, a Thomson Reuters business, Reuters reports.

4 Nov 2010

ADVENTRX submits NDA for Exelbine to FDA

ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.

3 Nov 2010

Questcor announces launch of H.P. Acthar Gel for infantile spasms

Questcor Pharmaceuticals, Inc. today announced that the commercial launch is now underway for H.P. Acthar® Gel (repository corticotropin injection) as monotherapy for the treatment of Infantile Spasms (IS) in infants and children under the age of two years. This new Acthar indication was approved by the U.S. Food and Drug Administration (FDA) on October 15, 2010.

3 Nov 2010

Lundbeck A/S third quarter revenue increases 7% to DKK 3,619 million

Danish-based H. Lundbeck A/S, a pharmaceutical company specialized in central nervous system (CNS) disorders, reports third quarter revenue of DKK 3,619 million, an increase of 7% compared to the third quarter results of 2009.

3 Nov 2010

EUREKA program confirms ability of HIFU technology to deliver cancer drugs

EDAP TMS SA the global leader in therapeutic ultrasound, reported today successful completion of feasibility studies aimed at improving delivery of cancer drugs using a combination of ultrasound sensitive liposomes and High Intensity Focused Ultrasound (HIFU).

3 Nov 2010

Scientists recommend research on bacterial vaccine to prevent influenza

Secondary infections with bacteria such as Streptococcus pneumoniae, which causes pneumonia, were a major cause of death during the 1918 flu pandemic and may be important in modern pandemics as well, according to a new article in the Journal of Infectious Diseases co-authored by David M. Morens, M.D., senior advisor to the director of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

3 Nov 2010

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA (methylphenidate HCl extended-release tablets).

3 Nov 2010

CONRAD receives $5 million award from USAID

CONRAD, leaders in reproductive health and HIV prevention research, today announced a $5 million award from the US Agency for International Development (USAID). The grant will fund research and development of vaginal rings that are contraceptive and also prevent HIV and STI infections.

3 Nov 2010

Somaxon awarded $245,000 grant for Silenor under QTDP program

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.

3 Nov 2010

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for OFIRMEV™ (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. OFIRMEV is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.

3 Nov 2010

UK watchdog agency to lose power to reject new drugs

The British government is expected to strip the National Institute for Health and Clinical Excellence, or NICE, of its ability to reject new drugs.

3 Nov 2010

Huber's Health & Nutrition business receives approval to produce active pharmaceutical ingredients

Huber Engineered Materials, a division of the J.M. Huber Corporation, has received approval for its Health & Nutrition business to begin producing active pharmaceutical ingredients (APIs), such as calcium carbonate granulation for use in the manufacturing of antacids and other pharma applications.

3 Nov 2010

Inviragen receives two grants to develop dengue and chikungunya vaccines

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, announced today that it has received two grants totaling $488,958 through the United States government's Qualifying Therapeutic Discovery Project Program.

3 Nov 2010

Talecris announces launch of PROLASTIN-C in Canada

Talecris Biotherapeutics announced today the Canadian launch of PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human])(A1PI), a more concentrated and purified formulation of PROLASTIN®, the only approved alpha1-augmentation therapy in Canada for more than 20 years. PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting the infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min.

3 Nov 2010

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).

2 Nov 2010